In this video, health-care analyst David Williamson discusses how Big Pharma is attempting to catch up when it comes to creating a next-gen hepatitis-C cure. Today's news features a collaboration between Merck and Bristol-Myers Squibb. Has Big Pharma missed the boat, or is there still time to get on board with a winning combination? Watch and find out.
Can it still make up ground with a winning hep-c drug cocktail?
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid